Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30594359 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CCNA2CDK2GPR119NPC1 | |
| SCHEMBL28876539 | 0.93 | BTK (0.55) | ALDH1A1CCNA2CDK2GPR119NPC1 | |
| SCHEMBL30085275 | 0.93 | BTK (0.55) | ALDH1A1CCNA2CDK2GPR119NPC1 | |
| SCHEMBL31170988 | 0.93 | BTK (0.55) | ALDH1A1CCNA2CDK2GPR119NPC1 | |
| SCHEMBL29124440 | 0.93 | BTK (0.55) | ALDH1A1CCNA2CDK2GPR119NPC1 | |
| SCHEMBL28876540 | 0.93 | BTK (0.55) | ALDH1A1CCNA2CDK2GPR119NPC1 | |
| SCHEMBL21811050 | 0.88 | POLB (0.47) | CCNA2CDK2GPR119BTKPOLB | |
| SCHEMBL31170960 | 0.88 | POLB (0.47) | CCNA2CDK2GPR119BTKPOLB | |
| SCHEMBL4715444 | 0.87 | ALDH1A1 (0.55) | ALDH1A1CCNA2CDK2GPR119NPC1 | |
| SCHEMBL1198309 | 0.86 | CCNA2 (0.55) | ALDH1A1CCNA2CDK2GPR119NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425504-A1 | IMIDAZOPYRIDINONE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (assignee) (JP) | 2024-12-26 | — | — | US | disclosed |
| EP-3808747-B1 | IMIDAZOPYRIDINONE COMPOUND | KISSEI PHARMACEUTICAL (JP) | 2024-12-18 | — | — | EP | disclosed |
| US-12077531-B2 | Imidazopyridinone compound | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2024-09-03 | — | — | US | disclosed |
| US-20240067645-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | LG CHEM, LTD. (KR) | 2024-02-29 | — | — | US | disclosed |
| WO-2024030651-A1 | GPX4 INHIBITORS AND USE THEREOF | SONATA THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| CN-112689637-B | Imidazopyridone compounds | 橘生药品工业株式会社 | 2023-11-10 | — | — | CN | disclosed |
| CN-116615199-A | Heterocyclic compounds as diacylglycerol kinase inhibitors and uses thereof | 株式会社LG化学 | 2023-08-18 | — | — | CN | disclosed |
| WO-2022114812-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2022-06-02 | — | — | WO | disclosed |
| EP-3092228-A1 | TRPA1 MODULATORS | Algomedix, Inc. (US) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015103060-A1 | TRPA1 MODULATORS | ALGOMEDIX, INC. (US) | 2015-07-09 | — | — | WO | disclosed |
| US-20110190336-A1 | AZABENZIMIDAZOLONES | CARA THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190336-A1 | AZABENZIMIDAZOLONES | CARA THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190336-A1 | AZABENZIMIDAZOLONES | CARA THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010045276-A2 | AZABENZIMIDAZOLONES | CARA THERAPEUTICS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077531-B2 | Imidazopyridinone compound | EGLN3, DHPS, EGLN2 | ALDH1A1 84/4885CCNA2 4289/4885CDK2 3333/4885 |
| US-20110190336-A1 | AZABENZIMIDAZOLONES | PTGER1, PTGDR, PTGER2 | ALDH1A1 1323/4885CCNA2 535/4885CDK2 360/4885 |
| US-20240425504-A1 | IMIDAZOPYRIDINONE COMPOUND | EGLN3, DHPS, EGLN2 | ALDH1A1 84/4885CCNA2 4289/4885CDK2 3333/4885 |
| US-20240067645-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | DGKA, DGKB, DGKK | ALDH1A1 2241/4885CCNA2 737/4885CDK2 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.